Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
Sienna Biopharmaceuticals Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
EnerCom Announces Initial List of Presenting Companies for the 31st Annual Energy Investment Conference to be held August 17-19, 2026, in Denver, Colorado
